Cell-Based Assays Market Expected to Reach $26 Billion by 2030 | CAGR by 8.2%

According to a new report published by Allied Market Research, titled, "Cell-Based Assays Market by Product, Application, and End User: Global Opportunity Investigation and Industry Forecast, 2021-2030” the global cell-based assay market size was worth $12 billion in 2020 and is expected to reach $26 billion by 2030, with a CAGR of 8.2% from 2022 to 2030.

Cell-based assay can be referred as any experiment that uses a live cell. A variety of cell-based assays can be used to measure cell toxicity, proliferation, motility, as well as the generation of a specific cellular product and cellular morphology. Cell-based assays are a better depiction of the real-life model because live cells are used in the experiment. Cell-based assays have evolved into a flexible tool in healthcare R&D, particularly in investigations aimed at understanding specific cell functions, such as antibody function or therapeutic efficacy on a set of cells. Cell-based tests are essential in the drug development process. In vitro biochemical assays have various advantages over cell-based techniques. In contrast to biochemical experiments, they provide consistent tissue-specific responses in a physiologically relevant milieu. Also, not every target for biochemical measurement can be prepared or purified, which is a major factor restricting biochemical assay uses.

The major factors that drive global cell-based assay market include pharmaceutical and biotechnology companies, as well as contract research organizations (CROs), which are replacing biochemical tests with cell-based assays in their drug discovery led identification and optimization procedures. Furthermore, traditional toxicity and drug safety assessment approaches (which involve animal testing) are costly, time-consuming, and low-throughput. In this sense, contemporary cell-based assays combine the benefits of cell cultures and animal models to allow researchers to uncover problems with lead compounds early in the drug discovery and development process, assuring higher efficiency. Cell-based assays' physiological relevance, as well as their capacity to provide efficient, cost-effective, and expedited drug development solutions, have spurred their increased popularity among end users. Various public and corporate entities have increased their R&D funding to discover better and safer pharmaceuticals. Furthermore, advances in cell-based assay technology have allowed researchers to use this method for drug discovery and toxicology studies. Another major factor attributing the growth of the market is the rise in prevalence of lifestyle diseases such as arthritis, diabetes, epilepsy, cancer, cardiovascular diseases, and others, which still have large unmet needs and have led to continuous investments in R&D. This market is also being driven by increase in the usage of cell-based assay techniques for high throughput screening methods, such as toxicity studies, drug screening, in vitro testing, and others.

 The World Health Organization (WHO) on January 30, 2020, declared COVID-19 outbreak a public health emergency of international concern. COVID-19 has affected around 210 countries across the globe. Due to the COVID-19 pandemic, governments across the globe announced country-wide lockdowns as well as social distancing measures to prevent collapse of the healthcare system. The overall impact of COVID-19 on the global cell-based assay market was positive owing to significant increment in chronic diseases, surge in funding in R&D sectors, surge in establishments of biotechnology and pharmaceutical manufacturing units, and rise in lifestyle disorders.

The cell-based assay market is segmented on the basis of product, application, end user, and region. On the basis of product, it is categorized into consumable, instrument, service, and software. The consumable segment includes, reagents, microplates, probes & labels, assay kits, cell lines, and others. Assay kits are further sub-divided into reporter gene assays, cell growth assays, second messenger assays, cell death assays, and others. Likewise, the cell lines are divided into immortalized cell lines, primary cell lines, and stem cell lines. By application, the market is divided into drug discovery; basic research; absorption, distribution, metabolism, & excretion (ADME) studies; predictive toxicology; and others. On the basis of end user, it is categorized into pharmaceutical & biotechnology companies, academic & government research institutes, contract research organizations, and others. On the basis of region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

On the basis of product, the cell-based assay market is segmented into consumables, instruments & software, and services. Consumables dominated the market due to the repeated purchase of consumables by pharmaceutical and biopharmaceutical companies.

On the basis of application, the cell-based assay market is categorized into drug discovery, basic research, and other applications. The drug discovery application segment dominated the market, which is attributed to increase in funding in the R&D sector, technological advancements, introduction of new drugs, surge in lifestyle disorders, the growing number of CROs providing drug discovery services, and surge in manufacturing units of biotechnology and pharmaceuticals.

On the basis of end users, the cell-based assay market is segmented into pharmaceutical and biopharmaceutical companies, CROs, and academic and research institutes. Pharmaceutical & biotechnology companies dominated the market in 2019. The large share of this segment can be attributed to the exposure of technology, increase in R&D expenditure, the growing number of drug discovery projects, growing number of chronic and lifestyle disorders, and the adoption of strategic approaches such as collaborations to develop drug candidates.

In addition, North America accounted for the largest share of the cell-based assays market, followed by Europe. The large share of the North American regional segment can be attributed to the availability of funding’s in R&D sectors, surge in lifestyle disorders, rise drug discovery, and the rapid adoption of advanced technologies in the region.

Key Findings Of Study

• The study gives a top to bottom investigation of the cell-based assay market, with most recent things and future appraisals to explain the imminent investment pockets.
• It gives a quantitative investigation from 2020 to 2030 to engage the accomplices to gain by prevailing market opportunities.
• Wide investigation by product type and end user determines the various trends and prevailing opportunities in the different market.
• Complete examination of all land regions is given, which assist with determining the main opportunities.
• Key market players are profiled and their strategies are investigated totally to expect the relentless standpoint of the cell-based assay market.